Locate Therapeutics changes name and receive £0.5 million investment from Mercia

Locate Bio Limited (“Locate” or “Company”) a specialist regenerative medicine company based in Nottingham, UK, has changed its name from Locate Therapeutics Limited and received a new direct investment of £0.5 million from Mercia Technologies PLC (AIM: MERC) (“Mercia”).

CEO Update | Monday 22 October

New explainer videos, new R+D tax guide, Commons’ Select committee on AMR and new Scientist.com deal It’s great to celebrate and explain our sector. Last week we launched our Celebrating UK Bioscience videos and re-vamped our Strategic Technologies webpage with fantastic new content. We generated just under half a million unique impressions on Twitter in 3 days, and I’d like you to share these resources with your network to drive better understanding of our sector and what it does.  

BIA responds to House of Commons Health and Social Care Committee report on antimicrobial resistance

The BioIndustry Association (BIA) has responded to the House of Commons Health and Social Care Committee report on antimicrobial resistance released today.

Synpromics Promoter Technology Moves Closer to the Clinic

Synpromics announces positive data presented today by uniQure at the European Society of Gene and Cell Therapy conference. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.

Excellent science, attracting global talent and investment, creating jobs, growth and delivering the therapies of the future – the state of the UK bioscience ecosystem in 2018

Commenting on the state of the UK life sciences ecosystem in a keynote address to the Bioindustry Association (BIA) UK Bioscience Forum in London BIA CEO Steve Bates OBE, will say: “The UK life sciences ecosystem is in a fantastic place. I see innovation, opportunity and collaboration everywhere. We are in an era of profound scientific opportunity.” The opening address will cover key issues that are currently having an impact on the UK bioscience ecosystem including government funding, Brexit, R&D development, the NHS and the future of the European Medicines Agency (EMA).

Blue Earth Diagnostics wins prestigious “Best Emerging Biotech” award

Oxford, UK – October 12, 2018 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, has won the Oxford Bio Network (OBN) award for “Best Emerging Biotech ”. These prestigious OBN awards, which are judged by a panel of leading industry entrepreneurs and experts, celebrate innovation and outstanding achievement across the UK’s Life Sciences industry.

Synpromics Unveils Next Generation Liver Selective and Tunable Promoter Platform

Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.

BIA launches videos and explainer documents celebrating UK bioscience and revealing the cutting-edge R&D taking place in biotech companies around the UK

The UK BioIndustry Association (BIA) has today launched a series of four explainer booklets and five videos that celebrate the fantastic work taking place in UK bioscience companies to create innovative new drugs and treatments for patients.